TVTXTravere Therapeutics, Inc.
Price
+110%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, growing in the filings, the market undecided.
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs. In September 2024, the U.S. Food and Drug Administration ("FDA") granted full approval to our lead development program, FILSPARI (sparsentan), which is indicated to slow kidney function decline in adults with primary Immunoglobulin A nephropathy ("IgAN") who are at risk of disease progression.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Travere Therapeutics, Inc. (TVTX) reported revenue of $170M in Q2 2026 (quarter ended Jun 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $35M. For the full year FY2025, revenue was $491M (+110% year on year) and net income −$26M. Its largest product in Q2 2026 was FILSPARI at $141M, 83% of the disclosed total, well ahead of Tiopronin Products at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the timeline and terms surrounding the planned transition of Dr. Dube, who will step down from his position as the Company’s President and Chief Executive Officer and as a member of the Board of Directors of the …Director or officer change · Form 8-K
- Aug 4, 2026Travere Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 9, 20265.02(b) On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027 (the …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $169.6MThe company’s own SEC segment disclosure.
- FILSPARI$141.1M83%
- Tiopronin Products$20.3M12%
- License$8.2M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.